• Global seladelpar launch team

• Managed global communications and budgets across virology therapeutic areas incl. HIV, HIV PrEP, COVID-19, HBV, HCV, HDV, and Inflammation• Congress planning for major liver conferences incl. AASLD & EASL

• Led development of a machine learning algorithm to detect undiagnosed hepatitis C (HCV)• Implemented and validated the HCV algorithm in electronic medical record systems across heterogenous integrated delivery networks (IDNs) in the United States and Australia• Conducted market research to optimize the user experience for customers including clinicians, population health managers, healthcare administrators, and patients• Managed interdisciplinary stakeholders including Clinical Research, Clinical Operations, Marketing, Regulatory, Government Affairs & Policy, Legal, external consultants, vendors, key opinion leaders, clinicians, data scientists, digital & connected health experts, product managers, patient advocates, professional societies, public health departments, IRBs, regulators, clinical research associates• Subject matter expertise in Software as a Medical Device (SaMD) and health technology

• Responsible for planning advisory boards and investigator meetings supporting the World Health Organization's goal to eliminate hepatitis C (HCV) as a public health threat by the year 2030

• Operational lead for hepatitis C (HCV) and non-alcoholic steatohepatitis (NASH) Phase 4 investigator-initiated research programs• Launched 5 Request for Proposal (RFP) programs resulting in support of 87 investigator-initiated studies in >30 countries

• Operational lead for hepatitis C (HCV) Phase 4 investigator-initiated research program• Responsible for the study conduct of 200+ studies and $25M research budget